You are here: Industry Insights > InnoCare

News List

Biogen pays $125 million upfront for rights to InnoCare's orelabrutinib in MS deal firstwordpharma
July 13, 2021
Biogen has agreed to pay InnoCare Pharma $125 million upfront for exclusive rights to the oral BTK inhibitor orelabrutinib for the potential treatment of multiple sclerosis (MS) worldwide and certain autoimmune diseases outside of China.
InnoCare Announces Approval of Initiation of Phase 1 Clinical Trial of RTK Inhibitor ICP-033 in China prnasia
June 28, 2021
InnoCare, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced that China's National Medical Products Administration (NMPA) has approved the initiation of a Phase I clinical trial of ICP-033, the Company's novel ...
InnoCare Announces Breakthrough Therapy Designation of Orelabrutinib by US FDA for Treatment of R/R MCL prnasia
June 28, 2021
InnoCare Pharma, a leading biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the treatment ...
InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma prnasia
June 21, 2021
InnoCare announced the company presented the latest clinical data of the Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib at the 16th International Conference on Malignant Lymphoma (ICML).
InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on MPresents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma prnasia
June 18, 2021
InnoCare announced today the company presented the latest clinical data of the Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib at the 16th International Conference on Malignant Lymphoma (ICML).
InnoCare Announces Orphan Drug Designation of Gunagrabtinib by US FDA for Treatment of Cholangiocarcinoma prnasia
June 17, 2021
InnoCare, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its pan-FGFR inhibitor gunagratinib (ICP-192) for the ...
Innocare Gets Approval from NMPA for Orelabrutinib contractpharma
January 08, 2021
Innocare has received approval by the National Medical Products Administration of China (NMPA) for Orelabrutinib, an orally available potent BTK inhibitor that irreversibly binds to BTK to induce downstream kinase inactivation and cell death.

Previous page 1 2 3 4 5 6 Next page